Dr. Gregory Lubiniecki
Medical OncologistDr. Gregory Lubiniecki is a medical oncologist at the Fox Chase Cancer Center in Philadelphia. He has experience treating pleural mesothelioma.
-
Fox Chase Cancer Center Philadelphia, Pennsylvania (PA)
-
Primary Location:Fox Chase Cancer Center -
Expertise:Radiation Oncology
Research -
Speciality:Medical Oncology -
Gender:Male -
Language:English -
Med School:Johns Hopkins University School of Medicine
Get to Know Dr. Gregory Lubiniecki
Like far too many of us, the life of Gregory Lubiniecki was forever changed by his family’s struggle with cancer in the early years of his life. While many facing such a challenge can feel overwhelmed with helplessness, Lubiniecki saw the experience as a call to action; his loved ones inspired him to enter the field of medicine and pursue a career in medical oncology.
After completing his medical training at Johns Hopkins University in 1998, Lubiniecki spent his residency studying internal medicine at Mayo Graduate School of Medicine. He went on to work as a medical oncologist at the Clinical Practices of the University of Pennsylvania before joining the Fox Chase Cancer Center in 2009.
A National Cancer Institute (NCI)-designated Comprehensive Cancer Center, Fox Chase is nationally recognized for its leadership in medical, radiation and surgical oncology. Here, Lubiniecki draws on his clinical expertise in mesothelioma and lung cancer to provide cancer patients with quality diagnosis, treatment and palliative care.
Multidisciplinary Approach
Lubiniecki takes a personalized, multidisciplinary approach to treatment. This means he and a diverse team of cancer specialists and health care team members work closely with each patient to meet his or her individual needs. He stresses the importance of effective communication between the doctor and patient, as well as between all the members of the patient’s care team.
Mesothelioma treatment begins with an accurate diagnosis. After the cancer is located with advanced imaging techniques or biopsy, Lubiniecki then identifies the tumor’s defining characteristics. This helps determine how the cancer will respond to different chemotherapy drugs. Further, this approach helps Lubiniecki and his team improve future treatments by pinpointing the tumor types that are resistant to specific drugs or a combination of several.
In addition to treating mesothelioma and lung cancer, Lubiniecki is also an active researcher. He strives to offer only the latest treatment options with the highest chance of success and minimal side effects.
